@Article{Dańczak-Pazdrowska2013,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="30",
number="6",
year="2013",
title="Original paperTransforming growth factor-β1 in plaque morphea",
abstract=" Introduction:  Morphea (localized scleroderma) is a rare cutaneous disease characterized by skin fibrosis of unknown pathogenesis. Transforming growth factor-β (TGF-β) is a potent profibrotic factor. The role of TGF-β in morphea remains unclear.    Aim:  The goal of this study was to estimate the expression level of TGF-β1 in skin and peripheral blood mononuclear cells as well as the plasma levels of TGF-β1 in plaque morphea (MEP).   Material and methods:  The study involved 20 MEP patients. Three control groups were involved: 1 – plasma: 36 healthy volunteers; 2 – PBMC: 47 healthy volunteers; 3 – skin biopsies: 13 samples collected during mastectomy (breast cancer was not skin involved). The analysis of TGF-β1 plasma levels was performed with the use an adequate ELISA kit, while real-time polymerase chain reaction was employed for the expression of TGF-β1 in peripheral blood mononuclear cells (PBMC) and skin.   Results:  In our study we have not detected differences in TGF-β 1 expression in PBMC, skin, nor in plasma levels of TGF-β1 between MEP patients and healthy controls, regardless of disease activity and its duration.   Conclusions: : The results of our study contradict the claim of the substantial role of TGF-β1 in the most common morphea subtype – MEP.",
author="Dańczak-Pazdrowska, Aleksandra
and Kowalczyk, Michał J.
and Szramka-Pawlak, Beata
and Gornowicz-Porowska, Justyna
and Szewczyk, Aleksandra
and Silny, Wojciech
and Molińska-Glura, Marta
and Olewicz-Gawlik, Anna
and Żaba, Ryszard
and Pazdrowski, Jakub
and Hrycaj, Paweł",
pages="337--342",
doi="10.5114/pdia.2013.39431",
url="http://dx.doi.org/10.5114/pdia.2013.39431"
}